In contrast, T-DM1, consisting of DM1 attached via a non-cleavable linker to trastuzumab, has a favorable toxicity profile and a clinically meaningful antitumor activity in HER2 positive breast cancer [17]. This evidence concerns the gene ERBB2 and breast cancer.